Biosimilars: Company strategies to capture value from the biologics market

Pharmaceuticals

Volumn 5, Issue 12, 2012, Pages 1393-1408

  Calo Fernández, Bruno ^a   Martínez Hurtado, Juan Leonardo ^b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Biologics; Biopharmaceutical industry; Biosimilar; Market strategy; Patent cliff

Indexed keywords

ADALIMUMAB; ATORVASTATIN; BEVACIZUMAB; BIOLOGICAL PRODUCT; CLOPIDOGREL; ERYTHROPOIETIN; ETANERCEPT; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; IMIGLUCERASE; INFLIXIMAB; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INTERFERON; MONOCLONAL ANTIBODY; RANIBIZUMAB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRASTUZUMAB; VENLAFAXINE;

ARTICLE; BIOTECHNOLOGY; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; EXPIRATION DATE; FINANCIAL MANAGEMENT; HEALTH CARE COST; PATENT; PHARMACEUTICS; POLITICS; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PROFIT; SOCIOECONOMICS;

EID: 84871478745     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph5121393     Document Type: Article

References (62)

1. DGC. Pharmaceutical Sector Inquiry Preliminar Report. Technical report, European Commission, Brussel, Belgium, 2008.
2. Bristol-Myers. 10-K Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2011.
3. Pfizer. 10-K Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2011.
4. Merck. 10-K Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2011.
5. Novartis. 20-F Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2011.
6. McCamish, M.; Woollett, G. Worldwide experience with biosimilar development. MAbs 2011, 3, 209-217.
7. EvaluatePharma. World Preview 2018 Embracing the Patent Cliff. Technical report, Evaluate Pharma, London, UK, 2012.
8. Shellenkens, H. When biotech proteins go off-patent. Trends Biotechnol. 2004, 22, 406-410.
9. Kellermann, S.; Green, L. Antibody discovery: The use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr. Opin. Biotechnol. 2002, 13, 593-597.
10. Amgen. 10-K Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2011.
11. NovoNordisk. 20-F Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2011.
12. Abbot. 10-K Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2011.
13. Centocor. 10-K Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2011.
14. RocheAG. 10-K Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2011.
15. Wroblewski, M.S. Emerging Healthcare Issues: Follow-on Biologic Drug Competition. Technical report, Federal Trade Commission, Washington, DC, USA, 2009.
16. Amgen springs Enbrel patent surprise. Nat. Rev. Drug Discov. 2012, 11, 9. Available online: http://www.nature.com/nrd/journal/v11/n1/full/nrd3644.html.
17. Browne, S.; Al-Rubeai, M. Selection methods for high-producing mammalian cell lines. Cell Line Dev. 2009, pp. 127-151.
18. Zheng, R. The game changer. BioProcess Int. 2010, 8, S4-S9.
19. McGlaughlin, M.S. An emerging answer to the downstream bottleneck. BioProcess Int. 2010, 10, 58-61.
20. WHO. Financial health care in the European Union, Challenges and policy responses. Technical report, World Health Organization, Geneva, Switzerland, 2009.
21. EMA. Guidelines on comparability of medical products containing biotechnology-derived proteins as active substance. Technical report, Euopean Medical Agency, Uppsala, Sweden, 2003.
22. EMA. Guidelines on Similar Medicinal Products Containing Recombinant Human Soluble Insulin. Technical report, European Medical Agency, Uppsala, Sweden, 2006.
23. EMA. Guidelines on Similar Medicinal Products Containing Somatropin. Technical report, Euopean Medical Agency, Uppsala, Sweden, 2006.
24. FDA. Biologics Price Competition and Innovation Act of 2009, x7002(b)(3). Technical report, Food and Drug Administration, Silver Spring, MD, USA, 2009.
25. Wang, J.; Chow, S. On the regulatory approval pathway of biosimilar products. Pharmaceuticals 2012, 5, 353-368.
26. Roger, S. Biosimilars: How similar or dissimilar are they? (Review Article). Nephrology 2006, 11, 341-346.
27. Schellekens, H. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin. Ther. 2002, 24, 1720-1740.
28. Fernandes, D. Demonstrating comparability of antibody glycosylation during biomanufacturing. Eur. Biopharm. Rev. 2005, pp. 106-110.
29. Usdin, S. The heparin story. Int. J. Risk Safety Med. 2009, 21, 93-103.
30. Shukla, A.; Thommes, J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010, 28, 253-261.
31. Locatelli, F.; Roger, S. Comparative testing and pharmacovigilance of biosimilars. Nephrol. Dial. Transplant. 2006, 21, v13-v16.
32. Roger, S.; Mikhail, A. Biosimilars: Opportunity or cause for concern? J. Pharm. Pharm. Sci. 2007, 10, 405-410.
33. Schneider, C.; Borg, J.; Ehmann, F.; Ekman, N.; Heinonen, E.; Ho, K.; Hoefnagel, M.; van der Plas, R.; Ruiz, S.; van der Stappen, A.; et al. In support of the European Union biosimilar framework. Nat. Biotechnol. 2012, 30, 745-748.
34. Schellekens, H.; Moors, E. Reply to in support of the European Union biosimilar framework. Nat. Biotechnol. 2012, 30, 748-749.
35. FDA.; CDER.; CBER.; USDHHS. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Technical report, Food and Drug Administration US, Silver Spring, MD, USA, 2012.
36. IndustryCanada. Pharmaceutical Industry Profile. Technical report, Government of Canada, 2012.
37. IMS. Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape. Technical report, Food and Drug Administration US, Silver Spring, MD, USA, 2011.
38. Lapointe, S.; Archambault, J.A. Importance of non-patent exclusivities in the life-cycle management of pharmaceuticals. Can. Intellect. Prop. Rev. 2011, 27, 115-138.
39. Moran, N. Fractured European market undermines biosimilar launches. Nat. Biotechnol. 2008, 26, 5-6.
40. Kessel, M. The problem with today's biopharmaceutical business: An outsider's view. Nat. Biotechnol. 2011, 29, 27-33.
41. Fitzgerald, G. Anticipating change in drug development: The emerging era of translational medicine and therapeutics. Nat. Rev. Drug Discov. 2005, 4, 815-818.
42. Chui, M. Despite global downturn, generics makers stand to reap great rewards in China's evolving pharmaceutical market. J. Generic Med. Bus. J. Generic Med. Sector 2009, 6, 230-236.
43. Huggett, B. Big pharma swallows Biotech's proud. Nat. Biotechnol. 2008, 26, 955-956.
44. Walker, J. Deal watch: M&A activity in 2009. Nat. Rev. Drug Discov. 2010, 9, 95-95.
45. Campbell, N.J. Mega-Mergers: Are they Turning Pharma Companies into Zombies? Pharma Focus Asia 2009, 9, 8-14.
46. Aggarwal, S. What's fueling the biotech engine 2010 to 2011. Nat. Biotechnol. 2011, 29, 1083-1089.
47. Aggarwal, S. What's fueling the biotech engine 2009 to 2010. Nat. Biotechnol. 2010, 28, 1165.
48. Scannell, J.; Blanckley, A.; Boldon, H.;Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 2012, 11, 191-200.
49. Pfizer. 10-K Financial Statements 2009. Technical report, Securities Exchange Commission, Washington, DC, USA, 2009.
50. Pfizer. 10-K Financial Statements 2010. Technical report, Securities Exchange Commission, Washington, DC, USA, 2010.
51. Pfizer. Pfizer Pipeline Report. Technical report, Pfizer, 2012.
52. Teva. 10-K Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2011.
53. Hospira. 10-K Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2011.
54. Ho, S.V.; McLaughlin, J.M.; Cue, B.W.; Dunn, P.J. Environmental considerations in biologics manufacturing. Green Chem. 2010, 12, 755-766.
55. Teva. 10-K Financial Statements 2004. Technical report, Securities Exchange Commission, Washington, DC, USA, 2004.
56. Teva. 10-K Financial Statements 2006. Technical report, Securities Exchange Commission, Washington, DC, USA, 2006.
57. Rivera, M.M.M. Marco Regulatorio de Medicamentos Biotecnologicos Comparables en Mexico. Technical report, Comision Federal para la Prevencion contra Riesgos Sanitarios, 2009.
58. ANVS. Registro de Produtos Biologicos Novos e Produtos Biologicos e d'outras Providencias. Technical report, Agencia Nacional de Vigilancia Sanitaria Diretoria Colegiada, Diario Oficial Republica Federativa do Brasil, 2010.
59. Pliva. Annual Report 2005. Technical report, Pliva, 2005.
60. Teva. 10-K Annual Report 2009. Technical report, Securities Exchange Commission, Washington, DC, USA, 2009.
61. Teva. 10-K Financial Statements 2011. Technical report, Securities Exchange Commission, Washington, DC, USA, 2010.
62. Amgen. Annual Report 2011. Technical report, Amgen Inc., 2011.